ELAVL1 and lung carcinoma: So FOXD3-AS1 in exosomes derived from lung cancer cells can upregulate the expression of ELAVL1 and activate the PI3K/Akt pathway to promote lung cancer progression and resistance to 5-FU, providing a new strategy for the treatment of lung cancer.